Allergy Therapeutics (LON:AGY) Stock Price Down 17.4% – Here’s What Happened

Allergy Therapeutics plc (LON:AGY)’s share price traded down 17.4% during trading on Tuesday . The company traded as low as GBX 9 and last traded at GBX 9. 165,235 shares were traded during trading, a decline of 40% from the average session volume of 277,293 shares. The stock had previously closed at GBX 10.90.

Allergy Therapeutics Stock Down 5.5%

The stock has a market cap of £652.25 million, a price-to-earnings ratio of -10.62, a P/E/G ratio of -30.70 and a beta of 0.91. The company has a current ratio of 1.13, a quick ratio of 1.48 and a debt-to-equity ratio of 629.58. The firm’s 50 day moving average is GBX 10.74 and its two-hundred day moving average is GBX 10.37.

Allergy Therapeutics (LON:AGY) last issued its quarterly earnings results on Tuesday, March 31st. The company reported GBX (0.38) EPS for the quarter. The firm had revenue of GBX 3,628 million for the quarter. Allergy Therapeutics had a positive return on equity of 409.00% and a negative net margin of 85.46%. On average, sell-side analysts predict that Allergy Therapeutics plc will post -2.56 EPS for the current year.

Allergy Therapeutics Company Profile

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.